Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.
Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK.
Wright RS, et al. Among authors: zang x.
Cardiovasc Res. 2024 Oct 14;120(12):1400-1410. doi: 10.1093/cvr/cvae109.
Cardiovasc Res. 2024.
PMID: 38753448
Free PMC article.
Clinical Trial.